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Introduction
Ghrelin is an important gastrointestinal hormone, 
which maintains the energy homeostasis by delivering 
neuroendocrine signals from the stomach to the brain (1,2).
Suboptimal nutrition, genetics, aberrations in insulin-like
growth factor-1 (IGF-1) and growth hormone (GH) axis have
all been accused as responsible factors in the etiology of
constitutional delay of growth and puberty (CDGP) (3,4,5,6).
We hypothesized that defects in both GH secretagogue and
orexigenic properties of ghrelin may contribute to delayed
growth. Studies on the possible role of ghrelin on growth
are limited in number. In this study, we compared plasma
ghrelin levels of normally growing children with those of
children with CDGP. 
Materials and Methods
Study Group
The study was conducted on thirty male children 
with CDGP between the ages of 10.5 and 15.5 years.  All
children were born at term with birth weights appropriate
for gestational age and had not suffered from any significant
health problems. Fifteen healthy male children of similar
ages constituted the control group. In 19 out of the 30
(63.3%) boys, the family history was positive for CDGP, and
none of subjects had a history of chronic illness, important
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taken from the children and their parents and the study was
approved by the local ethics committee. 
Weight and height measurements were done by the
same medical staff early in the morning. For the weight
measurement, a device (SECA©) with an accuracy of 0.1 kg
and maximum capacity of 150 kg was used. For the height
measurement, Harpenden stadiometer© (Holtain
Instruments Ltd, U.K) with an accuracy of 0.1cm was used,
in which, child was in erect position with heels, buttocks
and scapulae in contact with the device. Body mass index
(BMI) was calculated using the standard formula [BMI=
Weight (kg) / Height2 (meter)]. Evaluations of weight, height
and BMI, and their SDS calculations were performed
according to the charts prepared by Neyzi et al (7) for
Turkish children. Pubertal staging was determined by
Tanner’s classification (8). Prader’s orchidometer was used
for measurement of testicular volume (9). 
The heights of the children with CDGP were below the
third percentile (-2 SD); upper/lower segment ratios were
appropriate according to the standards (10). Bone age was
assessed according to the Greulich-Pyle atlas (1 ). The
bone ages of the children with CDGP were delayed with
respect to their chronological ages by at least two years.
Their physical examination findings were normal. The 
parents of the children with CDGP had normal height SDS
values. 
The children with CDGP were followed for at least one
year in our clinic. Their target heights were similar to their
predicted adult heights. 
Daily energy and protein intake for the children in both
groups were calculated by a dietician using a 3-day diet
record. No children had overt malnutrition. Complete blood
count, erythrocyte sedimentation rate, routine chemical
analysis including renal and liver function tests, urine analysis
and thyroid function tests were all normal for both groups.
Antigliadin and antiendomysium antibodies were negative
in all children, excluding celiac disease. 
Blood samples for ghrelin levels were obtained 
from antecubital veins at 08.00 a.m. after a twelve-hour
fast. Then, they received a standard breakfast arranged
according to their sex, age, height and weight. Two hours
after consuming that breakfast, blood samples were taken
for the postprandial ghrelin levels. Ethylenediamine
tetraacetic acid (EDTA) was used for anticoagulation of the
blood samples. After centrifugation, HCl (in 1/10 ratio) and
10-15 μL aprotinin (protease inhibitor) were added to the
samples for preservation. All samples were kept at -80°C.
ELISA method was used (Desacyl-Ghrelin-ELISA Kit, SCETI-
Mitsubishi Kagaku Iatron, (Tokyo, Japan) for measurement
of the total plasma ghrelin levels. Inter- and intra-assay 
coefficients were 3.7% and 8.1%, respectively; the 
detection limit was 3.68 pg/mL. The ELISA method was
also used for measurement of serum IGF-1 and IGFBP-3
levels (BIOSOURCE-ELISA Kit-Belgium).
Statistical Analysis        
All values were analyzed in SPSS 16.0 (SPSS software
for Windows, SPSS Inc, Chicago, IL) and showed a normal
distribution according to the Kolmogorov-Smirnov test.
Mann-Whitney U test was used to compare values
between groups and Pearson’s correlation analysis-to
investigate correlations between parameters. All values
were expressed as “mean±standard deviation”. “p” values
below 0.05 were accepted as significant. 
Results
The mean chronological ages in both groups were similar,
and the bone ages of children with CDGP were significantly
lower than those of the control group. Although the mean
weight and height values of children with CDGP were 
significantly lower than those of the control group, no 
significant difference was found in BMI values. The mean
weight and height SDS values of children with CDGP were
significantly lower than those of the control subjects; the
mean BMI SDS values were similar in both groups (Table 1). 
Table 2 shows the results for hormonal parameters in
the two groups. Mean serum IGF-1 and IGFBP-3 levels of
children with CDGP were lower than those of children in
the control group (p=0.001 and p=0.003). In children with
CDGP, IGF-1 and IGFBP-3 SDS levels calculated according
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Table 1.Anthropometric findings  of the children with CDGP and  ofthe
control group
CGDP Control group p
(n=30) (n=15)
Chronological age (years) 12.7±1.4 12.3±1.3 NS
Bone age (years) 10.6±1.1 12.0±1.2 <0.05
Height (cm) 139.1±0.4 153.5±9.6 <0.05
Weight (kg) 42.4±8.0 50.0±9.7 <0.05
BMI (kg/m2) 21.8±2.8 21.1±2.6 NS
BMI SDS 1.0±0.7 0.9±0.6 NS
Height SDS -2.3±0.1 0.2±0.6 <0.05
Weight SDS -0.7±0.8 0.5±0.8 <0.05
Mann-Whitney U test. NS: Nonsignificant (p>0.05); p<0.05=Significant.
CDGP: Constitutional delay of growth and puberty
1to chronological age were significantly lower (p=0.0001 and
p=0.0001), but they were similar when they were 
compared according to bone age (p=0.279 and p=0.114).
No significant differences existed in both fasting and 
postprandial ghrelin levels in children with CDGP and in 
children in the control group (p=0.427, p=0.112, respectively).
The difference in ghrelin levels between fasting and 
postprandial states in children with CDGP was
394.44±369.10 pg/mL (the drop in ghrelin levels with feeding
was 48%). In the control group, this difference was
346.55±338.67 pg/mL (the drop in ghrelin levels with 
feeding was 53%). The differences between fasting and
postprandial levels of ghrelin were similar in both groups
(p=0.885). 
In a 3-day diet record, children with CDGP had 
significantly lower daily calorie intake compared to the 
control group (1250 kcal/day versus 1880 kcal/day).
Correlations
As seen in Table 3, fasting ghrelin correlated negatively
with chronological age, bone age, height, weight, BMI and
BMI SDS, and IGF-1. Postprandial ghrelin level negatively
correlated only with weight, BMI and BMI SDS. 
Discussion
The cause of growth delay in CDGP is not clear. The
suggested role of partial and temporary functional 
hypopituitarism or partial and temporary GH deficiency has
not been documented (12,13,14,15). Since children with
CDGP show a growth pattern similar to that of undernourished
children, suboptimal nutrition from the early months of life
was reported to be a cause of CDGP (16,17). 
Horner et al (4) found that children with CDGP received an
insufficient daily food intake, which provided them with
fewer calories compared to children with normal growth
pattern. Failure to thrive in the early months of infancy is
reported to be present in most children with CDGP
(4,18,19). In animals, suboptimal nutrition caused hormonal
imbalance, which did not revert to normal following 
initiation of normal feeding (20). In rats, prolonged 
restriction of protein caused irreversible aberrations in 
GH-IGF-1 axis, which did not improve when the protein
restriction ceased (20). In previous studies, it was reported
that individuals who consumed a low-calorie diet had 
higher ghrelin levels compared to those who consumed a
normal-calorie diet and advocated that higher ghrelin levels
reflected a compensatory mechanism to increase food
intake (21). Thus, we expected to find higher ghrelin levels
in children with CDGP, who had lower daily calorie intake
compared to the children in the control group. In a similar
study, children with CDGP were found to have higher 
ghrelin levels than children with normal growth patterns, a
finding, which was also interpreted to be a compensatory
increase  (22). In the present study, however, we found 
similar ghrelin levels in children with CDGP and in the 
control group, so we were  not able to make any argument
about the role of ghrelin in growth delay. We could have
speculated that the fall in ghrelin levels with meals may be
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Table 2. Mean ghrelin, IGF-1, IGFBP-3 levels and their SDS values of
children with CGDP and  in the control group 
CGDP Control group p
(n=30) (n=15)
IGF-1 (ng/mL) 239.5±84.0 339.2±63.1 <0.05
IGF-1 SDS  -0.4±1.2 (CA*) 1.6±1.4 (CA*) <0.05
IGF-1 SDS  1.4±1.5 (BA**) 1.6±1.4 (CA*) NS
IGFBP-3 (mg/L) 3.1±0.5 3.6±0.4 <0.05
IGFBP-3 SDS  -1.4±1.5 (CA*) -0.1±0.5 (CA*) <0.05
IGFBP-3 SDS  -0.6±0.8 (BA**) -0.1±0.5 (CA*) NS
Fasting ghrelin (pg/mL) 824.23±523.46 687.38±481.43 NS
Postprandial ghrelin  447.26±259.92 365.59±260.43 NS
(pg/mL)
Difference between  
fastin gand   394.44±369.10 (48%) 346.55±338.67 (53%)NS
postprandial
ghrelin levels (pg/mL) 
Mann-Whitney U test. NS: Nonsignificant (p>0.05); p<0.05=Significant
CA*= According to chronological age, BA**= According to bone age
CDGP: constitutional delay of growth and puberty
Table 3. Fasting and postprandial ghrelin levels in children with CDGP,
evaluation by Pearson correlation analysis
Fasting ghrelin Postprandial ghrelin
Chronological *p=0.017, r= - 0.432 p=0.054, r=-0.355
age (years)
Bone age (years) *p=0.013, r=-0.450 p=0.055, r=-0.355
Height (cm) *p=0.001, r=-0.409 p=0.058, r=-0.121
Weight (kg) *p=0.001, r=-0.362 *p=0.005, r=-0.390
BMI (kg/m2) *p=0.035, r=-0.429 *p=0.014, r=-0.596
Height SDS p=0.880, r=-0.001 p=0.360, r=-0.030
Weight SDS p=0.251, r=0.047 p=0.158, r=0.070
BMI SDS *p=0.019, r=-0.365 *p=0.043, r=-0.402
IGF-1 *p=0.005, r=-0.495 p=0.009, r=-0.468
IGFBP-3     p=0.104, r=-0.303 p=0.314, r=-0.190
*p<0.05: Significantmore prominent in children with CDGP, they got satiety
more rapidly than normal children and consequently 
consumed less food, but our results do not support this
explanation either. The differences between fasting and
postprandial ghrelin levels were similar in children with
CDGP and in the control subjects.  We can only speculate
that there may be insensitivity to ghrelin in children with
CDGP. 
Since CDGP is seen more commonly in males, our
study group was composed of male children only. Weight
and height SDS values of children with CDGP were lower
than those of the control group. However, there were no
significant differences in the BMI and BMI SDS values
between the two groups. It is interesting that despite a low
caloric intake, the BMI values of the 2 groups were similar.
More in-depth and longitudinal studies may be needed to
investigate the role of acute and chronic undernutrition in
the etiology of CDGP. The similar BMI values in children
with CDGP and in the control group might also explain the
unchanged ghrelin levels found in this study. 
Wudy et al (23) found lower BMI values in children with
idiopathic short stature, and showed the importance of
nutrition in growth delay. In that study, similar to 
our results, the authors reported no difference in ghrelin
levels between children with idiopathic short stature and
children with normal growth. Park et al (24) found negative
correlations between ghrelin levels and anthropometric
parameters such as weight, height, BMI, waist circumference
and hip circumference in healthy children. In our study, we
observed that both fasting and postprandial ghrelin levels
correlated negatively to weight and BMI in children with
CDGP. Whatmore et al (25) showed that ghrelin decreased
with increased age. Our results were similar, but although a
negative correlation between ghrelin and both chronological
and bone ages was found in children with CDGP, such 
correlation was not detected in the control group. In our
study, height, weight and BMI were the most important
determinants of ghrelin levels in  children with CDGP as
well as in children in the control group.     
Whatmore et al (25) defined IGF-1 and IGFBP-1 as the
most important determining factors for ghrelin. In our
study, ghrelin levels negatively correlated with IGF-1, but
did not correlate with IGFBP-3. The negative correlation
between ghrelin and IGF-1 may be related to the inhibitory
effects of ghrelin on peripheral IGF-1 actions. In contrast to
ghrelin, insulin levels are highest after meals and at lower
levels just before meals.  IGFBP-1 levels change in parallel
to ghrelin levels (26). The dynamic interactions between
ghrelin, insulin and IGFBP-1 show that ghrelin affects IGF-1
and insulin actions at tissue level. Thus, in our study, 
we found that as ghrelin levels rise, IGF-1 levels drop. In
puberty, IGF-1 levels increase and IGFBP-1 levels decline,
which is in parallel to increased growth (25,26). These 
findings show us that ghrelin does not stimulate growth
directly, but affects growth indirectly through its effect on
the interactions within the  IGF-1-GH axis (25,26). 
In our study, IGF-1, IGFBP-3 and their SDS values were
lower in children with CDGP as compared to children in the
control group. When we calculated IGF-1 and IGFBP-3 SDS
values according to bone age, no difference was found in
SDS values between the two groups. Evaluation of IGF-1,
IGFBP-3 and their SDS values must be made according 
to bone age, rather than chronological age in children of
pubertal ages. 
Lower IGF-1 levels in children with CDGP were probably
an outcome of suboptimal nutrition, rather than GH 
deficiency. Although ghrelin levels were similar in the study
and the control groups, unidentified  defects in  ghrelin
effect in children with CDGP might have caused growth
delay indirectly by decreasing food intake. Our results are
insufficient to clarify the role of ghrelin in growth delay in
children and show that there are still many unknown points
related to both ghrelin and CDGP. 
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